Active Biotech AB Asset Resilience Ratio
Active Biotech AB asset resilience ratio. Active Biotech AB (ACTI) has an Asset Resilience Ratio of 92.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Active Biotech AB (ACTI) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Active Biotech AB (2000–2025)
Asset resilience ratio of Active Biotech AB from 2000 to 2025. This chart shows how Active Biotech AB's Asset Resilience Ratio has changed over time. Read Active Biotech AB (ACTI) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Active Biotech AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ACTI total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr65.10 Million | 92.74% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr65.10 Million | 92.74% |
Asset Resilience Insights
- Very High Liquidity: Active Biotech AB maintains exceptional liquid asset reserves at 92.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Active Biotech AB Industry Peers by Asset Resilience Ratio
Compare Active Biotech AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Active Biotech AB Asset Resilience Ratio by Year (2000–2025)
Active Biotech AB asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Active Biotech AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 92.74% | Skr65.10 Million ≈ $7.01 Million |
Skr70.20 Million ≈ $7.55 Million |
+29.32pp |
| 2024-12-31 | 63.41% | Skr27.39 Million ≈ $2.95 Million |
Skr43.20 Million ≈ $4.65 Million |
-18.81pp |
| 2023-12-31 | 82.23% | Skr36.22 Million ≈ $3.90 Million |
Skr44.05 Million ≈ $4.74 Million |
+0.27pp |
| 2022-12-31 | 81.95% | Skr41.80 Million ≈ $4.50 Million |
Skr51.01 Million ≈ $5.49 Million |
-11.59pp |
| 2021-12-31 | 93.54% | Skr53.13 Million ≈ $5.72 Million |
Skr56.80 Million ≈ $6.11 Million |
+12.02pp |
| 2020-12-31 | 81.52% | Skr26.21 Million ≈ $2.82 Million |
Skr32.16 Million ≈ $3.46 Million |
-7.62pp |
| 2019-12-31 | 89.14% | Skr59.68 Million ≈ $6.42 Million |
Skr66.95 Million ≈ $7.21 Million |
+80.69pp |
| 2018-12-31 | 8.45% | Skr25.55 Million ≈ $2.75 Million |
Skr302.43 Million ≈ $32.55 Million |
+0.17pp |
| 2017-12-31 | 8.28% | Skr25.15 Million ≈ $2.71 Million |
Skr303.81 Million ≈ $32.70 Million |
-10.53pp |
| 2016-12-31 | 18.81% | Skr77.68 Million ≈ $8.36 Million |
Skr412.88 Million ≈ $44.43 Million |
+17.48pp |
| 2004-12-31 | 1.33% | Skr4.17 Million ≈ $449.19K |
Skr312.89 Million ≈ $33.67 Million |
-51.44pp |
| 2003-12-31 | 52.77% | Skr182.27 Million ≈ $19.62 Million |
Skr345.40 Million ≈ $37.17 Million |
+18.55pp |
| 2002-12-31 | 34.22% | Skr159.98 Million ≈ $17.22 Million |
Skr467.50 Million ≈ $50.31 Million |
-28.76pp |
| 2001-12-31 | 62.98% | Skr470.96 Million ≈ $50.68 Million |
Skr747.74 Million ≈ $80.47 Million |
+27.54pp |
| 2000-12-31 | 35.45% | Skr308.02 Million ≈ $33.15 Million |
Skr868.95 Million ≈ $93.51 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye disea… Read more